Cargando…

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model

BACKGROUND: Renal cell carcinoma (RCC) patients treated with tyrosine kinase inhibitors (TKI) typically respond initially, but usually develop resistance to therapy. We utilised transcriptome analysis to identify gene expression changes during development of sunitinib resistance in a RCC patient-der...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diaz-Montero, C Marcela, Mao, Frances J, Barnard, John, Parker, Yvonne, Zamanian-Daryoush, Maryam, Pink, John J, Finke, James H, Rini, Brian I, Lindner, Daniel J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061902/ https://www.ncbi.nlm.nih.gov/pubmed/27560553 http://dx.doi.org/10.1038/bjc.2016.263

Ejemplares similares

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
por: Wang, X, et al.
Publicado: (2013)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
por: Donskov, Frede, et al.
Publicado: (2015)

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
por: Mahalingam, D, et al.
Publicado: (2011)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience
por: Ströbel, P, et al.
Publicado: (2010)

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
por: Boven, E, et al.
Publicado: (2010)

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
por: Zurita, A J, et al.
Publicado: (2015)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Phenformin as prophylaxis and therapy in breast cancer xenografts
por: Appleyard, M V C L, et al.
Publicado: (2012)

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
por: Voss, Martin H, et al.
Publicado: (2016)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma
por: Santos, C D, et al.
Publicado: (2015)

Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts
por: Eicher, C, et al.
Publicado: (2013)

Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts
por: Chiu, M, et al.
Publicado: (2014)

Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans
por: Alonzi, R, et al.
Publicado: (2009)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy
por: Tan, Q, et al.
Publicado: (2015)

In vivo effects of rosiglitazone in a human neuroblastoma xenograft
por: Cellai, I, et al.
Publicado: (2010)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
por: Morgillo, F, et al.
Publicado: (2011)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts
por: Liu, J, et al.
Publicado: (2007)

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts
por: Vlahovic, G, et al.
Publicado: (2007)

Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
por: Perez-Gracia, J L, et al.
Publicado: (2009)

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
por: Beloueche-Babari, M, et al.
Publicado: (2013)

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
por: Smalley, K S M, et al.
Publicado: (2007)

Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer
por: Harrington, Brittney S, et al.
Publicado: (2016)

Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells
por: Fung, M K L, et al.
Publicado: (2006)

O(6)-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts
por: Clemons, M, et al.
Publicado: (2005)

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours
por: Baro, M, et al.
Publicado: (2014)

Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer
por: Barnes, N L P, et al.
Publicado: (2007)

Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour
por: Kölby, L, et al.
Publicado: (2005)

Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts
por: Chaudary, Naz, et al.
Publicado: (2017)

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
por: Yuen, J S P, et al.
Publicado: (2011)

Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms
por: Legrier, M-E, et al.
Publicado: (2007)

Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition
por: Byrne, N M, et al.
Publicado: (2016)

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
por: Broutin, Sophie, et al.
Publicado: (2016)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation
por: de Plater, L, et al.
Publicado: (2010)

Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-γ
por: Ribatti, D, et al.
Publicado: (2006)

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA
por: Henare, K, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_i1gs1q11midn2oeb77jocr9pp0